CMS has reached agreements with bluebird bio and Vertex Pharmaceuticals for their FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia, respectively.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
CMS partners with 2 companies on sickle cell therapies
